- Report
- December 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 139 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- September 2021
- 40 Pages
China
From €2481EUR$2,600USD£2,079GBP
- Report
- August 2022
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2020
- 80 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- August 2024
- 80 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- April 2023
- 90 Pages
Middle East, Africa
From €4533EUR$4,750USD£3,798GBP
- Report
- September 2019
- 28 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- March 2019
- 20 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Report
- October 2023
- 107 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP

Sorafenib is a drug used to treat advanced skin cancer. It is a type of targeted therapy, meaning it works by targeting specific molecules involved in the growth and spread of cancer cells. It is used to treat advanced melanoma, a type of skin cancer, and is also used to treat other types of cancer, such as kidney and liver cancer. Sorafenib works by blocking the action of certain proteins that are involved in the growth and spread of cancer cells. It is usually taken in pill form, and is usually taken twice a day.
Sorafenib is a relatively new drug, and is still in the early stages of development. It is not yet widely available, and is only approved for use in certain countries. However, it is becoming increasingly popular as a treatment for advanced skin cancer, and is being studied for use in other types of cancer.
The Sorafenib market is highly competitive, with many companies vying for a share of the market. Some of the major players in the market include Bayer, Novartis, Pfizer, and Merck. Other companies in the market include GlaxoSmithKline, AstraZeneca, and Eli Lilly. Show Less Read more